Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653730 | 0.87 | ROCK2 (0.60) | ROCK2ROCK1MMP3 | |
| SCHEMBL7454854 | 0.87 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL91397 | 0.87 | ROCK2 (0.62) | ROCK2ROCK1MMP3 | |
| SCHEMBL3653731 | 0.86 | ROCK2 (0.61) | ROCK2ROCK1MMP3 | |
| Hydrochloric Acid SCHEMBL355183 | 0.85 | ROCK1 (0.66) | ROCK2ROCK1 | |
| SCHEMBL3653728 | 0.84 | ROCK2 (0.59) | ROCK2ROCK1MMP3 | |
| SCHEMBL7144846 | 0.83 | ROCK2 (0.58) | ROCK2ROCK1MMP3 | |
| SCHEMBL6316630 | 0.82 | ROCK2 (0.62) | ROCK2ROCK1MMP3 | |
| SCHEMBL6880276 | 0.81 | ROCK2 (0.65) | ROCK2ROCK1MMP3 | |
| SCHEMBL7447830 | 0.78 | ROCK2 (0.65) | ROCK2ROCK1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125883-B1 | Integrin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20040259864-A1 | Substituted pyrimidinone derivatives as ligands of integrin receptors | ABBOTT GMBH & CO. KG (DE) | 2004-12-23 | — | — | US | disclosed |
| CN-1374960-A | novel integrin receptor antagonists | BASF AG (DE) | 2002-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259864-A1 | Substituted pyrimidinone derivatives as ligands of integrin receptors | ITGB3, ITGA5, ITGB5 | ROCK2 2519/4885ROCK1 2717/4885CYP1A2 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.